Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann C Collier

Showing results (101-110 of 184) with videos related to

Pageof 19
Sort By:
The Journal of Clinical Investigation|June 4, 2024
Antigen specificities and proviral integration sites differ in HIV-infected cells by timing of antiretroviral treatment initiationJaimy Joy, Ana Gervassi, Lennie Chen, et al.
Annals of Neurology|December 11, 2008
Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathyRonald J Ellis, Jennifer Marquie-Beck, Patrick Delaney, et al.
Neurology|December 16, 2014
Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected peopleDavid B Clifford, Florin Vaida, Yu-Ting Kao, et al.
The Journal of Antimicrobial Chemotherapy|January 22, 2013
Etravirine in CSF is highly protein boundAnh Nguyen, Steven Rossi, David Croteau, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 6, 2009
Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infectionLinda G Apuzzo, Florin Vaida, Joel E Gallant, et al.
Plos Pathogens|April 21, 2017
Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activationRajesh T Gandhi, Deborah K McMahon, Ronald J Bosch, et al.
Plos One|May 19, 2010
Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infectionEric S Rosenberg, Barney S Graham, Ellen S Chan, et al.
The Journal of Infectious Diseases|August 23, 2003
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus diseaseMargaret A Fischl, Heather J Ribaudo, Ann C Collier, et al.
Journal of Virology|July 31, 2015
Fitness-Balanced Escape Determines Resolution of Dynamic Founder Virus Escape Processes in HIV-1 InfectionJustine E Sunshine, Brendan B Larsen, Brandon Maust, et al.
The Journal of Antimicrobial Chemotherapy|November 25, 2010
Efavirenz concentrations in CSF exceed IC50 for wild-type HIVBrookie M Best, Peter P Koopmans, Scott L Letendre, et al.
Pageof 19

Showing results (101-110 of 184) with videos related to

Sort By:
Pageof 19
The Journal of Clinical Investigation|June 4, 2024
Antigen specificities and proviral integration sites differ in HIV-infected cells by timing of antiretroviral treatment initiationJaimy Joy, Ana Gervassi, Lennie Chen, et al.
Annals of Neurology|December 11, 2008
Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathyRonald J Ellis, Jennifer Marquie-Beck, Patrick Delaney, et al.
Neurology|December 16, 2014
Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected peopleDavid B Clifford, Florin Vaida, Yu-Ting Kao, et al.
The Journal of Antimicrobial Chemotherapy|January 22, 2013
Etravirine in CSF is highly protein boundAnh Nguyen, Steven Rossi, David Croteau, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 6, 2009
Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infectionLinda G Apuzzo, Florin Vaida, Joel E Gallant, et al.
Plos Pathogens|April 21, 2017
Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activationRajesh T Gandhi, Deborah K McMahon, Ronald J Bosch, et al.
Plos One|May 19, 2010
Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infectionEric S Rosenberg, Barney S Graham, Ellen S Chan, et al.
The Journal of Infectious Diseases|August 23, 2003
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus diseaseMargaret A Fischl, Heather J Ribaudo, Ann C Collier, et al.
Journal of Virology|July 31, 2015
Fitness-Balanced Escape Determines Resolution of Dynamic Founder Virus Escape Processes in HIV-1 InfectionJustine E Sunshine, Brendan B Larsen, Brandon Maust, et al.
The Journal of Antimicrobial Chemotherapy|November 25, 2010
Efavirenz concentrations in CSF exceed IC50 for wild-type HIVBrookie M Best, Peter P Koopmans, Scott L Letendre, et al.
Pageof 19